[003 mimic #1 scientific] Metabolic quirks yield tumor hope_Hailey

Metabolic quirks yield tumour hope

Early clinical-trial results show promise for targeting cancer-related biochemical pathways.

Heidi Ledford

Cancer cells harness unusual metabolic pathways to obtain the energy and molecular building blocks that they need for their relentless proliferation. Many potential drugs have tried to take advantage of this hunger. Early results for a genetically targeted drug, unveiled this week at the annual meeting of the American Association for Cancer Research in San Diego, California, suggest that the approach could pay off.

In some ways, the findings send cancer research back to its roots. For much of the twentieth century, the disease was considered a metabolic malady — an idea that arose in the 1920s, when the German biochemist Otto Warburg showed that cancer cells have an outsized appetite for glucose. The glucose is broken down, yielding energy in the form of ATP, produced in the cell’s mitochondria, as well as components of amino acids, lipids and other compounds needed to build new cells.

First trial

Cancer cells use unusual metabolic pathways to generate energy and building blocks for their relentless proliferation. Many anti-tumor drugs were designed to target this hunger. During the Annual Meeting of Cancer Research in San Diego, researchers have shown that many genetic targeting drugs may pay off.

In some way, the finding sends cancer research back to its roots. During the 1920, the disease was considered as a metabolic meledy. A German scientist W has shown that cancer cells have excess appetite for glucose. The glucose was metabolized into energy in the form of ATP, and so are the other components, such as amino acid, lipid, and other components needed to build the cell.

Second trial

Cancer cells harness unusual metabolic pathways to obtain the energy and molecular building blocks in order to meet thethat they need forof their relentless proliferation. Many potential drugs have tried totaken advantage of this hunger. Early results for a genetically targeteding drugs, unveiled this week at thein Annual MeetingAmerican Association forof Cancer Research, in San Diego, California, suggest that these approaches could pay off.

In some way, the findings send cancer research back to its roots. For much of the twenties century, the disease was considered as a metabolic malady-an idea that arose around the 1920s, when a German biochemist OW showed that cancer cells have an outsized appetite for glucose. The glucose is broken down, yielding into energy, in the form of ATP, producedhappens in the cells’ mitochondria, as well as the other components of, amino acid, lipid, and other compounds required to buildfor building new cell.